An extent of resection threshold for newly diagnosed glioblastomas
2011/03/18 by Nader Sanai, Mei-Yin Polley, Mei‐Yin C. Polley +3 · 1,659 citations
Medicine · #Brain Metastases and Treatment #Glioblastoma #Glioma Diagnosis and Treatment #Internal medicine #Medicine #Meningioma and schwannoma management #Oncology #Proportional hazards model #Recursive partitioning #Surgery #Survival analysis
paper · doi:10.3171/2011.2.jns10998
published in Journal of neurosurgery 115(1), 3-8 (American Association of Neurological Surgeons)
openalex publication_date 2011/03/18 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Abstract
OBJECT: The value of extent of resection (EOR) in improving survival in patients with glioblastoma multiforme (GBM) remains controversial. Specifically, it is unclear what proportion of contrast-enhancing tumor must be resected for a survival advantage and how much survival improves beyond this threshold. The authors attempt to define these values for the patient with newly diagnosed GBM in the modern neurosurgical era. METHODS: The authors identified 500 consecutive newly diagnosed patients with supratentorial GBM treated at the University of California, San Francisco between 1997 and 2009. Clinical, radiographic, and outcome parameters were measured for each case, including MR imaging-based volumetric tumor analysis. RESULTS: The patients had a median age of 60 years and presented with a median Karnofsky Performance Scale (KPS) score of 80. The mean clinical follow-up period was 15.3 months, and no patient was unaccounted for. All patients underwent resection followed by chemotherapy and radiation therapy. The median postoperative tumor volume was 2.3 cm(3), equating to a 96% EOR. The median overall survival was 12.2 months. Using Cox proportional hazards analysis, age, KPS score, and EOR were predictive of survival (p < 0.0001). A significant survival advantage was seen with as little as 78% EOR, and stepwise improvement in survival was evident even in the 95%-100% EOR range. A recursive partitioning analysis validated these findings and provided additional risk stratification parameters related to age, EOR, and tumor burden. CONCLUSIONS: For patients with newly diagnosed GBMs, aggressive EOR equates to improvement in overall survival, even at the highest levels of resection. Interestingly, subtotal resections as low as 78% also correspond to a survival benefit.
Citations
Cited by
- Novel approaches to targeting gliomas at the leading/cutting edge
- A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas
- Outcome Prediction in Patients with Glioblastoma by Using Imaging, Clinical, and Genomic Biomarkers: Focus on the Nonenhancing Component of the Tumor
- Supratotal resection of diffuse gliomas – an overview of its multifaceted implications
- EANS-EANO guidelines on the extent of resection in gliomas
- Weakly-Supervised Learning-Based Feature Localization in Confocal Laser Endomicroscopy Glioma Images
- Wide-Field Mueller Polarimetry of Brain Tissue Sections for Visualization of White Matter Fiber Tracts
- Deep Learning versus Classical Regression for Brain Tumor Patient Survival Prediction
- Prospects for Theranostics in Neurosurgical Imaging: Empowering Confocal Laser Endomicroscopy Diagnostics via Deep Learning
- Multiple resections for patients with glioblastoma: prolonging survival. [europepmc]
- Neuronavigation in the surgical management of brain tumors: current and future trends. [europepmc]
- Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. [europepmc]
- Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. [europepmc]
- Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. [europepmc]
- Detection of human brain cancer infiltration ex vivo and in vivo using quantitative optical coherence tomography. [europepmc]
- Current Applications of MRI-Guided Laser Interstitial Thermal Therapy in the Treatment of Brain Neoplasms and Epilepsy: A Radiologic and Neurosurgical Overview. [europepmc]
- Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy. [europepmc]
- Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. [europepmc]
- Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma. [europepmc]
- Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. [europepmc]
- Applications of Ultrasound in the Resection of Brain Tumors. [europepmc]
- Overcoming therapeutic resistance in glioblastoma: the way forward. [europepmc]
- A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. [europepmc]
- Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. [europepmc]
- Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy. [europepmc]
- Advances in Brain Tumor Surgery for Glioblastoma in Adults. [europepmc]
- Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes. [europepmc]
- 5-ALA and FDA approval for glioma surgery. [europepmc]
- Genetic and molecular epidemiology of adult diffuse glioma. [europepmc]
- Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. [europepmc]
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. [europepmc]
- Radioresistance in Glioblastoma and the Development of Radiosensitizers. [europepmc]
- A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. [europepmc]
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. [europepmc]
Related